CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Maintenance or reduction of immunosuppressionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2408 T89 Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease

This will be a randomized trial of maintenance versus reduction in immunosuppression in adult patients (age >18 years old) with functioning renal transplants admitted to hospital with confirmed COVID-19 disease.

NCT04420364 COVID Kidney Transplant; Complications Immunosuppression Other: Maintenance or reduction of immunosuppression

Primary Outcomes

Measure: Change in IL-6 concentration from baseline to day 7

Time: baseline to day 7

Secondary Outcomes

Measure: Change in IL-6 concentration from baseline to day 28

Time: Baseline to day 28

Measure: Change in T cell response to SARS-CoV-2

Time: Baseline to day 7 and day 28

Measure: Change in titer of serum anti-SARS-CoV-2 antibodies

Time: Baseline to day 7 and day 28

Measure: Change in COVID-19 disease severity score (range 1 to 8; higher worse)

Time: Through day 28

Measure: Proportion of patients needing non-invasive ventilation or intubation

Time: Through day 28

Measure: Proportion of patients developing ANC < 500 cells per microliter

Time: Through day 28

Measure: Proportion of patients developing lymphopenia < 400 cells per microliter

Time: Through day 28

Measure: Length of hospital stay

Time: Through day 28

Measure: Proportion of patients developing biopsy-proven acute rejection

Time: Through day 28

Measure: In-hospital and 28-day mortality

Time: Through day 28

Measure: Adverse and serious adverse events

Time: Through day 28


No related HPO nodes (Using clinical trials)